home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CymaBay Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >

CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 3/21

March 21, 2024

Via Investor Brand Network

Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production ↗

March 15, 2024

Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a...

Via Benzinga

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs ↗

March 14, 2024

As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)

February 29, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/21

February 21, 2024

Via Investor Brand Network

CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/13

February 13, 2024

Via Investor Brand Network

CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 1/25

January 25, 2024

Via Investor Brand Network

CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY

February 16, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Via MarketBeat

Topics Artificial Intelligence

CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst ↗

February 13, 2024

Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800...

Via Benzinga

Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high ↗

February 13, 2024

The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday. U.S. stocks closed mixed on Monday, with the Dow Jones index climbing to a fresh high during the session.

Via Benzinga

Topics Economy Stocks

6 Analysts Have This to Say About CymaBay Therapeutics ↗

December 15, 2023

Via Benzinga

Recap: CymaBay Therapeutics Q3 Earnings ↗

November 07, 2023

Via Benzinga

Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B ↗

February 12, 2024

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500...

Via Benzinga

Topics Stocks

Dow Up Triple Digits, Hits Fresh Highs ↗

February 12, 2024

Stocks are on the rise today, as investors towards tomorrow's inflation data.

Via Talk Markets

Topics Economy Stocks

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)

February 12, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Earnings Outlook For CymaBay Therapeutics ↗

November 06, 2023

Via Benzinga

Where CymaBay Therapeutics Stands With Analysts ↗

November 06, 2023

Via Benzinga

Why is CymaBay (CBAY) Stock Up 25% Today? ↗

February 12, 2024

CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences.

Via InvestorPlace

CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday ↗

February 12, 2024

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.

Via Benzinga

Topics Stocks

Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics ↗

February 12, 2024

Via Benzinga

CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders

February 12, 2024

From Halper Sadeh LLC

Via Business Wire

Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B ↗

February 12, 2024

Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue...

Via Benzinga

CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition ↗

February 12, 2024

The company is working on a treatment for primary biliary cholangitis, a liver disease treatment.

Via Investor's Business Daily

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

February 12, 2024

From Gilead Sciences, Inc.

Via Business Wire

Why CymaBay Morphed From Dollar Stock To Biotech Rocket ↗

December 28, 2023

The company is working on the first treatment that could make a difference in the itching associated with a liver disease.

Via Investor's Business Daily

Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know ↗

November 08, 2023

Via Benzinga

Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today ↗

October 23, 2023

It became increasingly likely that seladelpar will ultimately gain regulatory approval.

Via The Motley Fool

7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio ↗

September 27, 2023

Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.

Via InvestorPlace

UBS Maintains Buy Rating for CymaBay Therapeutics: Here's What You Need To Know ↗

September 26, 2023

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com